8-K: Coeptis Therapeutics & Z Squared Business Combination Update

Z Squared, Inc. provides supplemental information on its business combination with Coeptis Therapeutics Holdings, Inc. and a pro rata dividend distribution.

Summary

• Z Squared, Inc. (ZSQR) issued a press release on April 27, 2026, to provide additional details regarding its business combination with Coeptis Therapeutics Holdings, Inc.
• The company also detailed a pro rata dividend distribution of shares held in its subsidiary, Coeptis Holdings, Inc.
• Shareholders of record as of January 2, 2026, will receive one non-transferable share of Coeptis Holdings, Inc. common stock for each share of Z Squared common stock they hold.
• This distribution is effective on April 27, 2026.
• Z Squared's common stock began trading on the Nasdaq Global Market under the ticker symbol 'ZSQR' on April 27, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update, confirming expected corporate actions and stock trading commencement, but without new financial performance data.

Positives

• Confirmation of the pro rata dividend distribution to shareholders.
• Effective date of the dividend distribution is today, April 27, 2026.
• Z Squared's common stock commenced trading on Nasdaq under 'ZSQR' on April 27, 2026.

Risks

• The company's ability to execute its business strategy.
• Competition in the computing infrastructure and digital asset industries.
• Changes in power costs, energy regulation, and grid conditions.
• Hardware availability, pricing, and obsolescence.
• The company's ability to maintain and expand its facility footprint.
• Volatility of cryptocurrency markets and digital asset values.
• Market, economic, and capital markets conditions.
• Regulatory developments affecting the company's operations.

Future Outlook

The press release contains forward-looking statements regarding the expected commencement of trading of Z Squared's common stock on Nasdaq, the company's business strategy, operational plans, growth prospects, the expected benefits of its vertically integrated computing infrastructure model, its ability to scale, and its future financial and operational performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially.

Management Comments

• Z Squared, Inc. (Company) today issued supplemental information related to its previously announced business combination with Coeptis Therapeutics Holdings, Inc. and its pro rata dividend distribution related to Coeptis Therapeutics Holdings, Inc.s pre-business combination biopharmaceutical business.
• The Company announced that the pro rata distribution of shares held by the Company in its subsidiary Coeptis Holdings, Inc. will be issued to shareholders of record on January 2, 2026, as previously disclosed.
• Each holder of record of the Companys common stock will receive one share of non-transferable Coeptis Holdings, Inc. common stock for every share held.
• The distribution will be effected today, April 27, 2026.
• As previously announced, the Companys common stock is expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" today, Monday, April 27, 2026.

Industry Context

StockSavvy.ai notes that this filing details the separation of a biopharmaceutical business from a computing infrastructure company, a complex corporate restructuring that can unlock value for shareholders by allowing each entity to focus on its distinct market and strategic objectives. The dual listing and dividend distribution are common mechanisms for such spin-offs.

Stakeholder Impact

• Shareholders will receive shares in Coeptis Holdings, Inc., potentially diversifying their investment and benefiting from the focused strategy of the biopharmaceutical business.
• Employees of Z Squared, Inc. will continue to be employed by the computing infrastructure company.
• Employees of Coeptis Holdings, Inc. will be part of the entity pursuing biopharmaceutical development.

Next Steps

• Shareholders of record on January 2, 2026, will receive shares of Coeptis Holdings, Inc.
• Coeptis Therapeutics Holdings, Inc. will proceed with its business combination.
• Z Squared, Inc. will continue to operate its computing infrastructure business.

Key Dates

Recommendation

The filing confirms expected corporate actions and the commencement of trading for Z Squared, Inc. on Nasdaq. While this provides clarity, it does not offer new financial performance data or strategic shifts that would warrant a strong buy or sell recommendation at this juncture. Investors should await further performance updates from both Z Squared and Coeptis Therapeutics.

Keywords

business combination, dividend distribution, Coeptis Therapeutics, Z Squared, Nasdaq, ZSQR, computing infrastructure, biopharmaceutical